The multicenter European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion (CAM): thrombolysis versus conservative therapy [Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie].

Trial Profile

The multicenter European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion (CAM): thrombolysis versus conservative therapy [Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Retinal vascular occlusion
  • Focus Therapeutic Use
  • Acronyms EAGLE
  • Most Recent Events

    • 25 Aug 2011 Additional trial identifiers DRKS00000088, UKF000500 identified as reported by German Clinical Trials Register.
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register)
    • 11 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top